Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Quintiliani

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Pharmacotherapy|April 10, 2002
Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospitalEdward M Grant, Joseph L Kuti, David P Nicolau, et al.
International Journal of Antimicrobial Agents|July 25, 2016
Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltrationJoseph L Kuti, Islam M Ghazi, Richard Quintiliani, et al.
Pharmacotherapy|February 13, 2013
Comparative pharmacokinetics, pharmacodynamics, and tolerability of ertapenem 1 gram/day administered as a rapid 5-minute infusion versus the standard 30-minute infusion in healthy adult volunteersDora E Wiskirchen, Seth T Housman, Richard Quintiliani, et al.
The Annals of Pharmacotherapy|May 3, 2007
Treatment of Serratia marcescens meningitis with prolonged infusion of meropenemAnthony M Nicasio, Richard Quintiliani, C Andrew DeRyke, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|November 29, 2002
Pharmacoeconomics of a pharmacist-managed program for automatically converting levofloxacin route from i.v. to oralJoseph L Kuti, Thuy N Le, Charles H Nightingale, et al.
Infection Control and Hospital Epidemiology|November 24, 2015
Assessment of Clostridium difficile Burden in Patients Over Time With First Episode Infection Following Fidaxomicin or VancomycinSeth T Housman, Abrar K Thabit, Joseph L Kuti, et al.
Journal of Bacteriology|December 3, 2003
The CroRS two-component regulatory system is required for intrinsic beta-lactam resistance in Enterococcus faecalisYannick Comenge, Richard Quintiliani, Ling Li, et al.
The American Journal of Managed Care|November 4, 2004
Acute exacerbation of chronic bronchitis: a primary care consensus guidelineStephen Brunton, Blaine P Carmichael, Richard Colgan, et al.
The Annals of Pharmacotherapy|April 16, 2013
Pharmacokinetics of doripenem in infected patients treated within and outside the intensive care unitAmira A Bhalodi, Rebecca A Keel, Richard Quintiliani, et al.
Chemotherapy|May 16, 2002
Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and 4.5G Q6HHolly M Mattoes, Blair Capitano, Myo-Kyoung Kim, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Pharmacotherapy|April 10, 2002
Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospitalEdward M Grant, Joseph L Kuti, David P Nicolau, et al.
International Journal of Antimicrobial Agents|July 25, 2016
Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltrationJoseph L Kuti, Islam M Ghazi, Richard Quintiliani, et al.
Pharmacotherapy|February 13, 2013
Comparative pharmacokinetics, pharmacodynamics, and tolerability of ertapenem 1 gram/day administered as a rapid 5-minute infusion versus the standard 30-minute infusion in healthy adult volunteersDora E Wiskirchen, Seth T Housman, Richard Quintiliani, et al.
The Annals of Pharmacotherapy|May 3, 2007
Treatment of Serratia marcescens meningitis with prolonged infusion of meropenemAnthony M Nicasio, Richard Quintiliani, C Andrew DeRyke, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|November 29, 2002
Pharmacoeconomics of a pharmacist-managed program for automatically converting levofloxacin route from i.v. to oralJoseph L Kuti, Thuy N Le, Charles H Nightingale, et al.
Infection Control and Hospital Epidemiology|November 24, 2015
Assessment of Clostridium difficile Burden in Patients Over Time With First Episode Infection Following Fidaxomicin or VancomycinSeth T Housman, Abrar K Thabit, Joseph L Kuti, et al.
Journal of Bacteriology|December 3, 2003
The CroRS two-component regulatory system is required for intrinsic beta-lactam resistance in Enterococcus faecalisYannick Comenge, Richard Quintiliani, Ling Li, et al.
The American Journal of Managed Care|November 4, 2004
Acute exacerbation of chronic bronchitis: a primary care consensus guidelineStephen Brunton, Blaine P Carmichael, Richard Colgan, et al.
The Annals of Pharmacotherapy|April 16, 2013
Pharmacokinetics of doripenem in infected patients treated within and outside the intensive care unitAmira A Bhalodi, Rebecca A Keel, Richard Quintiliani, et al.
Chemotherapy|May 16, 2002
Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and 4.5G Q6HHolly M Mattoes, Blair Capitano, Myo-Kyoung Kim, et al.
Pageof 3